An open-label multicenter, randomized, phase 3 study of S-1 in combination with cisplatin against 5-Fu [fluorouracil] in combination with cisplatin in patients with advanced gastric cancer previously untreated with chemotherapy for advanced disease.

Trial Profile

An open-label multicenter, randomized, phase 3 study of S-1 in combination with cisplatin against 5-Fu [fluorouracil] in combination with cisplatin in patients with advanced gastric cancer previously untreated with chemotherapy for advanced disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin; Fluorouracil
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms FLAGS
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 12 Sep 2017 Results of identification of patient population with longer survival by using clinical covariate model data from FLAGS and DIGEST phase III trials presented at the 42nd European Society for Medical Oncology Congress
    • 06 Jun 2017 Results (n=889) of an analysis discovering clinically significant covariate model to identify a patient population with longer survival presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Oct 2012 Results of a non-inferiority analysis presented at the 37th Congress of the European Society for Medical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top